FDA Plans Consumer Survey To Better Understand Cosmetics Allergy Prevalence
This article was originally published in The Rose Sheet
The agency will accept public comment for 60 days on its proposed survey to gain insight into “consumer use of cosmetic products, the frequency of adverse events believed to be caused by allergens in cosmetics, consumer awareness of the problem, and actions (if any) taken to avoid the allergens.”
You may also be interested in...
In a March 5 statement, FDA Commissioner Scott Gottlieb included labeling disclosure of known cosmetic allergens among elements that could be included in a modernized system for cosmetics oversight. The agency’s planned consumer survey, designed to assess “allergy to cosmetics,” could help to inform exploratory steps in that direction.
The ingredients at issue already must be labeled on cosmetic products in the EU due to their recognized sensitization and allergy potential. FDA expects to award the contract by the end of September, and finished work will be due to the agency within 18 months thereafter.
FDA’s release of AER data removes some secrecy surrounding cosmetic product adverse events but could create a false alarm about the industry. The data dump comes as Congress is considering legislation that would mandate that cosmetics firms provide FDA with reports of serious adverse events they receive.